What is Veradermics 's cash & equivalents?

Veradermics (MANE) reported cash & equivalents of $168.41M in Q1 2026.

What does cash & equivalents mean?

Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Veradermics MANE Cash & Equivalents

Cash & Equivalents at other companies

Travel + LeisureTNL

$456M+24.3%

Warrior Met CoalHCC

$210.55M-54.5%

Main Street CapitalMAIN

$20.79M-81.0%

Cabot CorporationCBT

$252M+18.3%

UnifirstUNF

$151.79M-21.0%

HES

Hess MidstreamHESM

$4.6M-24.6%

Other financials

Income statement

See full

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Balance sheet

See full

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Cash flow

See full

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Valuation

See full

Market cap$4.99B+296%

Returns & leverage

See full

Return on equity-28.7%—

Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Veradermics 's cash & equivalents?: Veradermics (MANE) reported cash & equivalents of $168.41M in Q1 2026.
What does cash & equivalents mean?: Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.